-
Systemic Safety in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration: A Patient-Level Pooled Analysis
-
Long-Term Outcomes of Ranibizumab Treatment of Myopic Choroidal Neovascularization In East-Asian Patients From the Radiance Study
-
Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study
-
Apathy in Neurodegenerative Diseases: Recommendations on the Design of Clinical Trials
-
Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders
-
Use of a relapse monitoring board: an independent assessment for determining relapse in clinical trials for bipolar disorder
-
Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms
-
Health care resource utilization and costs in a commercially insured population of patients with bipolar disorder type I and frequent psychiatric interventions
-
Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)
-
Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results
-
Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium
-
A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia
-
Characteristics, healthcare utilization and costs of bipolar disorder type I patients with and without frequent psychiatric intervention in a Medicaid population
-
Clinical characteristics and resource utilization of patients with bipolar disorder who have frequent psychiatric interventions
-
Assessment of clinician awareness of nonadherence using a new structured rating scale
-
Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia
-
A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism
-
A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently
-
Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study
-
A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life
-
Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study)
-
Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study
-
A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression
